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Background-—The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low-density lipoprotein-
cholesterol (LDL-C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated
alirocumab 150 mg Q4W in patients with inadequately controlled hypercholesterolemia and not on statin (majority with statin-
associated muscle symptoms), receiving treatment with fenofibrate, ezetimibe, or diet alone.
Methods and Results-—Patients were randomly assigned to placebo, alirocumab 150 mg Q4W or 75 mg Q2W (calibrator arm),
with dose adjustment to 150 mg Q2W at week (W) 12 if W8 predefined LDL-C target levels were not met. The primary efficacy
endpoint was LDL-C percentage change from baseline to W24. Mean baseline LDL-C levels were 163.9 mg/dL (alirocumab
150 mg Q4W, n=59), 154.5 mg/dL (alirocumab 75 mg Q2W, n=116), and 158.5 mg/dL (placebo, n=58). In the alirocumab
150 mg Q4W and 75 mg Q2W groups (49.1% and 36.0% of patients received dose adjustment, respectively), least-squares mean
LDL-C changes from baseline to W24 were 51.7% and 53.5%, respectively (placebo [+4.7%]; both groups P<0.0001 versus
placebo). In total, 63.9% and 70.3% of alirocumab-treated patients achieved their LDL-C targets at W24. Treatment-emergent
adverse events occurred in 77.6% (alirocumab 150 mg Q4W), 73.0% (alirocumab 75 mg Q2W), and 63.8% (placebo) of patients,
with injection-site reactions among the most common treatment-emergent adverse events.
Conclusions-—Alirocumab 150 mg Q4W can be considered in patients not on statin with inadequately controlled hypercholes-
terolemia as a convenient option for lowering LDL-C.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT02023879. ( J Am Heart Assoc. 2016;5:
e003421 doi: 10.1161/JAHA.116.003421)
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S tatins lower low-density lipoprotein cholesterol (LDL-C)by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A
reductase and consistently reduce cardiovascular disease
(CVD) risk by 30% to 40%.1-3 Therefore, statin therapy is
currently the recommended standard-of-care treatment for
lowering LDL-C in patients at increased CVD risk.2,3 In
contrast to all major randomized controlled trials, which have
found comparable rates of muscle adverse events (AEs)
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between statin and placebo arms,4-6 observational studies
reported higher rates of statin-associated muscle symptoms
(SAMS) in 7% to 29% of patients.7 As a consequence, patients
with SAMS often receive a suboptimal statin dose or no
statin therapy.7 A substantial proportion of these, often high-
risk, patients have persistently elevated LDL-C levels
(>190 mg/dL),8-10 placing them at a correspondingly high
CVD risk.3,11
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a
key regulator of cholesterol homeostasis, is a novel and
attractive therapeutic target for lowering LDL-C levels via a 3-
hydroxy-3-methylglutaryl-coenzyme A reductase-independent
pathway. Alirocumab, a fully human monoclonal antibody that
specifically binds to PCSK9, has been shown to significantly
lower LDL-C levels across a range of dosing regimens,
whether as monotherapy12 or on a background of statin-
other lipid-lowering therapies.13-16 A monthly dosing regimen
may be convenient and effective,17,18 with different doses
being appropriate when used as monotherapy compared with
background statin therapy. This is because statins are known
to increase PCSK9 levels,19 which reduce duration of
alirocumab effect in the setting of every 4 weeks (Q4W)
dosing.
Alirocumab 150 mg Q4W monotherapy demonstrated a
47.4% reduction in LDL-C levels from baseline in a phase 1
study.17 However, in an early phase 2 study of patients with
heterozygous familial hypercholesterolemia on statin, there
was only an incremental LDL-C reduction of 28.9% at week 12
with alirocumab 150 Q4W.18 The use of higher doses (200-
300 mg Q4W) resulted in greater incremental LDL-C reduc-
tions (42.5-47.7% at week 12) when added to stable statin
therapy.18,20
In this phase 3, placebo-controlled study (ODYSSEY
CHOICE II, NCT02023879), we evaluated the efficacy and
safety of alirocumab 150 mg Q4W (with possible adjustment
to 150 mg Q2W; referred to as “150Q4W”) as a therapeutic
option for patients with hypercholesterolemia not receiving
statin. This study also employed an alirocumab dosing
regimen of 75 mg every 2 weeks (Q2W; with possible dose
adjustment to 150 mg Q2W; referred to as “75Q2W”) as a
calibrator arm, a dose that has been extensively investigated
across the phase 3 ODYSSEY clinical trials program.12-16
CHOICE II followed a “treat-to-target” dosing strategy, based
on the LDL-C reduction needed to provide best achievement
of target LDL-C level at the lowest alirocumab dose.
Methods
ODYSSEY CHOICE II was a randomized, double-blind, placebo-
controlled, phase 3 multinational study including 233 patients
from 43 study sites from Australia (n=3), Belgium (n=3),
Canada (n=6), Denmark (n=5), the Netherlands (n=9), New
Zealand (n=2), Spain (n=7), and the United States (n=8). The
study was initiated on December 16, 2013 (first patient
screened) with the first patient randomized on January 2,
2014 and the last patient randomized on May 12, 2014. The
study was conducted in accordance with the ethical principles
in the Declaration of Helsinki and applicable amendments,
and the International Conference on Harmonisation guidelines
for Good Clinical Practice. The protocol was approved by the
relevant institutional review boards or independent ethics
committees. All participating patients provided written
informed consent.
Patients
The study enrolled adult patients (≥18 years of age) with
hypercholesterolemia receiving fenofibrate or ezetimibe or
diet alone. Only patients not receiving a statin were eligible
for the study, which corresponded to patients who (1) had
SAMS (which was defined as statin intolerance in the
protocol) with moderate, high, or very high cardiovascular
risk or (2) were not receiving a statin but who did not fulfill the
SAMS definition: only patients at moderate cardiovascular risk
were included in this stratum. SAMS, as well as moderate,
high, and very high cardiovascular risk, were defined as
previously described.21
SAMS, defined as statin intolerance in the study protocol,
was defined as the inability to tolerate at least 2 statins,
consistent with other studies in the ODYSSEY clinical trial
program21: 1 statin at the lowest daily starting dose (defined
as rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg,
lovastatin 20 mg, pravastatin 40 mg, fluvastatin 40 mg, or
pitavastatin 2 mg), and another statin at any dose, due to
SAMS, other than those due to strain or trauma, such as pain,
aches, weakness, or cramping, that began or increased during
statin therapy and stopped when statin therapy was
discontinued.
The aim was for two-thirds of randomized patients to be
receiving fenofibrate/ezetimibe, and for ≥50% of patients to
fulfill the SAMS definition. Patients were instructed to
maintain a stable diet (National Cholesterol Education
Program Adult Treatment Panel III Therapeutic Lifestyle
Changes diet or equivalent) throughout the entire study
duration, including the screening period.22 Use of fibrates
(other than fenofibrate), niacin, bile acid-binding sequestrants,
or red yeast rice products was not allowed during the study. A
list of exclusion criteria is given in Table S1.
Hypercholesterolemia was defined based on cardiovascular
risk: LDL-C ≥70 mg/dL if very high cardiovascular risk, or
LDL-C ≥100 mg/dL if high or moderate risk. In addition, for
those patients not fulfilling the SAMS definition, or who were
being treated with diet alone, LDL-C also had to be ≥100 and
<160 mg/dL.
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Study Procedures
The study comprised a 3-week screening period, followed by
24 weeks of double-blind treatment and 8 weeks of follow-up
(off treatment) for those patients who did not enter the open-
label treatment period (Figure 1). After screening, the planned
randomization was to follow a 2:1:1 treatment ratio for
alirocumab 150Q4W, alirocumab 75Q2W (calibrator arm), and
placebo Q2W, respectively. Randomization was stratified by
SAMS status and by either ezetimibe/fenofibrate therapy or
diet alone. However, owing to a systematic error in the
algorithm managing treatment allocation at the study setup
(where alirocumab 75Q2W was allocated to patients random-
ized to alirocumab 150Q4W during the entire double-blind
period and vice versa), patients were actually randomized in a
1:2:1 ratio to receive alirocumab 150Q4W, 75Q2W, or
placebo in a blinded manner. The blinding was maintained
for patients randomized to alirocumab 150Q4W by alternating
active and placebo injections; each patient received 12
injections during the study period. Each treatment was
administered subcutaneously by 1-mL prefilled pen.
On-site visits took place during the double-blind period at
weeks 0 (baseline, ie, the randomization visit), 4, 8, 9, 10, 11,
12, 16, and 24.
Patients in the alirocumab 150 mg Q4W or 75 mg Q2W
treatment groups who did not achieve their target LDL-C
levels (<70 or <100 mg/dL, depending on CVD risk), or who
did not achieve a reduction of ≥30% in LDL-C level from
baseline at week 8, had their alirocumab regimen changed to
150 mg Q2W at week 12 in a blinded fashion.
Patients also had the option of entering an open-label
treatment period after completion of the double-blind treat-
ment period. In this treatment period all patients received
alirocumab 150Q4W at week 36 based on the investigator’s
judgment.
Endpoints
The primary efficacy endpoint was the percentage change in
LDL-C (calculated using the Friedewald equation) from
baseline to week 24 in the intent-to-treat (ITT) population,
using all LDL-C values within 1 of the analysis windows up to
week 24 regardless of adherence to treatment (ie, ITT
approach). Efficacy endpoints were also assessed using an
on-treatment approach, using all LDL-C values during the
efficacy treatment period.
A hierarchical procedure was used to control type I error
and handle multiple key secondary endpoints. Those end-
points included the percentage change in calculated LDL-C
from baseline to week 24 using the on-treatment approach,
the percentage change in calculated LDL-C from baseline to
week 12 (also averaged for weeks 9-12), the proportion of
patients achieving predefined LDL-C targets of <70 or
<100 mg/dL, depending on cardiovascular risk, at weeks
Figure 1. CHOICE II study design. *Patients were to be randomized to 2:1:1 alirocumab 150Q4W: alirocumab 75Q2W: placebo. However, a
systematic randomization error occurred in alirocumab treatment allocation. †Blind was maintained in all patients, including those receiving dose
adjustments, by giving the study treatment as a single 1-mL subcutaneous injection Q2W in all groups. 75Q2W indicates 75 mg every 2 weeks
(with possible dose adjustment to 150 mg every 2 weeks); 150Q4W, 150 mg every 4 weeks (with possible dose adjustment to 150 mg every
2 weeks); LDL-C, low-density lipoprotein cholesterol; NCEP ATP III TLC, National Cholesterol Education Program Adult Treatment Panel III
Therapeutic Lifestyle Changes; Q2W, every 2 weeks; Q4W, every 4 weeks; R, randomization; W, week.
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12 and 24, and the percentage change in other lipid
parameters such as apolipoprotein B, non-high-density
lipoprotein cholesterol, total cholesterol, lipoprotein(a) (Lp
[a]), fasting triglycerides, high-density lipoprotein cholesterol,
and apolipoprotein A1 from baseline to weeks 12 and 24. All
comparisons with the alirocumab 75 mg Q2W treatment arm
were classed as other secondary endpoints.
Analyses of lipid samples were conducted by a central
laboratory. Lp(a) was analyzed using an immunoturbidimetric
assay on a Siemens BNII analyzer (Siemens, Erlangen,
Germany), with a reference range of 1 to 30 mg/dL. If
triglyceride values exceeded 400 mg/dL (4.52 mmol/L),
LDL-C was measured via b-quantification rather than by
calculation. (LDL-C ultracentrifugation was performed using a
Beckman Ultracentrifuge with an ultracentrifuge rotor, Type
50.4; LDL-C concentration was assessed using a Beckman
Coulter chemistry analyzer.) LDL-C was also measured via the
b-quantification method at weeks 0 and 24 in all patients.
Safety was assessed primarily from the reporting of
treatment-emergent AEs (TEAEs), defined as those occurring
during the period from first to last study drug injection plus
70 days or up to the first open-label injection, whichever
came first.
Certain events were classed as safety events of interest,
requiring completion of a special electronic case report form
(e-CRF), including general allergic reactions, cardiovascular
events, injection-site reactions, hemolytic anemia, neurologic
events, ophthalmologic events, and increased alanine amino-
transferase (ALT) levels. See Appendix S1 for further details
on safety events of interest and preferred terms for the
adverse events categories.
To assess development of antidrug antibodies to alirocu-
mab, blood samples were collected before study drug
administration at baseline and scheduled clinic visits at
weeks 4, 8, 12, 16, 24, and at the follow-up visit. These
samples were analyzed using a validated nonquantitative,
titer-based bridging immunoassay by Regeneron Pharmaceu-
ticals, Inc (Tarrytown, NY), using a tiered approach involving 3
potential steps: initial screen, confirmation, and a titer
measurement. Assay sensitivity was ~5.6 ng/mL based on
the positive control monoclonal antibody, and the drug
tolerance limit was 191 lg/mL of alirocumab for 500 ng/
mL of monoclonal antibody positive control. Positive samples
were tested for the presence of antidrug antibody using a
validated, nonquantitative, competitive ligand-binding assay
with sensitivity based on a monoclonal positive control
neutralizing antibody of 470 ng/mL. Drug tolerance limit
was 547 ng/mL of alirocumab in neat serum for 500 ng/mL
of monoclonal antibody positive control. Free PCSK9 levels
were determined using a specific validated enzyme-linked
immunosorbent assay (Regeneron Pharmaceuticals, Tarry-
town, NY). The lower limits of detection were 31.2 ng/mL.
Statistical Analysis
A sample size of 39 patients (26 in alirocumab 150Q4W and
13 in placebo arms, respectively) was estimated to have 90%
power to detect a between-treatment-group difference in
mean percentage change in LDL-C of 30%, with a 5% 2-sided
significance level and assuming a common standard deviation
of 25%, and a 5% nonevaluable primary endpoint. To obtain
additional safety data on the administration of a 150Q4W
regimen in non-statin-treated patients, the total planned
sample size was increased and rounded to 200 (100 for
alirocumab 150Q4W, 50 for alirocumab 75Q2W, and 50 for
placebo). Thus, the systematic allocation error was not
anticipated to have an impact on the power of the study.
The primary efficacy analysis was conducted in the ITT
population, which included all randomized patients with an
evaluable primary endpoint. Analysis utilized a mixed-effect
model with repeated measures to account for missing data as
used in previous alirocumab studies.23
Secondary lipid endpoints were analyzed as for the primary
endpoint, except Lp(a) and triglycerides (analyzed by multiple
imputation followed by a robust regression model) and LDL-C
goal achievement (analyzed by multiple imputation followed
by logistic regression). The modified ITT population used for
on-treatment analyses included all randomized patients with
an evaluable primary endpoint during the treatment period
who had received at least 1 dose or part of a dose of study
treatment.
The safety population included all randomized patients who
had received at least 1 dose or part of a dose of study drug.
Safety data were analyzed by descriptive statistics.
Device-Handling Questionnaire
At weeks 0 and 12, an optional device-handling questionnaire
assessed experience of participants performing self-injection
using the alirocumab prefilled pen.
Participants rated 7 manipulations/steps to inject alirocu-
mab/placebo (7-point scale from “not easy at all” [1] to
“extremely easy” [7]), how many clicks they heard during
injection, satisfaction with duration of injection (7-point scale
from “extremely unsatisfied” [1] to “extremely satisfied” [7]), and
the overall experience performing self-injection (7-point scale
from “extremely unsatisfied” [1] to “extremely satisfied” [7]).
Results
Patients
A total of 233 patients were randomly assigned to alirocumab
150Q4W (n=59), 75Q2W (n=116), and placebo (n=58)
(Figure 1, Figure S1). The ITT, modified ITT, and safety
populations comprised 230, 228, and 231 patients,
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respectively. A total of 158 (90.3%) randomized patients
receiving alirocumab completed the 24-week treatment
period. Reasons for study discontinuation are given in
Table S2.
Baseline characteristics and lipid parameters were gener-
ally balanced between groups (Table 1). A total of 90.1% of
patients fulfilled the criteria for SAMS as the reason for statin
discontinuation. The majority of patients with additional lipid-
lowering therapy received ezetimibe (60.1%) and/or fenofi-
brate (8.6%). Across the different treatment groups, 32.2% of
patients received treatment with diet alone and 3.4% received
nutraceuticals (Table 1).
Efficacy Analyses
Alirocumab (both dose regimens) maintained LDL-C reduc-
tions from week 4 (first sampling point) until week 24
(Figure 2; Table 2).
Week 12
Before any dose adjustment (ie, up to week 12), the mean
percentage change in LDL-C from baseline to averaged weeks
9 to 12 was 52.3% in the alirocumab 150Q4W group and
3.2% in the placebo group. However, in the alirocumab
150Q4W group the mean percentage reduction in LDL-C from
baseline to weeks 9 to 11 was greater (54.5% to 57.2%)
compared with that observed at week 12 (41.7%; Table 2).
Absolute LDL-C levels over time are shown in Figure 2. In the
alirocumab 75Q2W calibrator arm, percentage reduction in
LDL-C from baseline to averaged weeks 9 to 12 was 53.6%
(Table 2), whereas percentage reduction in LDL-C from
baseline to weeks 9 to 11 (51.6% to 56.3%) was comparable
to that at week 12 (50.8%).
At week 12, 26 patients (49.1%) received a dose adjust-
ment from alirocumab 150 mg Q4W to 150 mg Q2W because
these patients did not achieve their predefined LDL-C target
levels at week 8 (with 36.0% of patients in the 75 mg Q2W
group also increasing to 150 mg Q2W). In general, subjects in
both groups with dose adjustment were characterized by
higher LDL-C levels at baseline (197.5 mg/dL in the 150Q4W
group and 188.6 mg/dL in the 75Q2W group) compared with
those who did not require dose adjustment (130.3 and
137.3 mg/dL, respectively) (Figure 3, Table S3). Mean LDL-C
levels in patients who received dose adjustment from 150 mg
Q4W to 150 mg Q2W were reduced further from 120.5 mg/
dL at week 12 to 79.0 mg/dL at week 24, a decrease from
week 12 of 34.4%, corresponding to an incremental benefit of
~19% compared with baseline (Figure 3). Of patients allocated
to alirocumab 150Q4W, 50.9% did not need dose adjustment
and were maintained on this dose until the end of the study.
In the calibrator arm, 64.0% of patients remained on the
75 mg Q2W dose. For patients who received dose adjustment
from 75 mg Q2W to 150 mg Q2W, an LDL-C reduction from
week 12 to week 24 of 15.8% was observed, corresponding to
an incremental benefit of ~11% compared with baseline (week
12, 106.6 mg/dL; week 24, 89.8 mg/dL) (Figure S2).
Week 24
At week 24 (primary endpoint), the mean (standard error)
percentage change in LDL-C from baseline to week 24 was
greater in the alirocumab 150Q4W group (51.7%) versus
placebo (+4.7%) in the ITT analysis, with a statistically
significant mean difference of 56.4% (P<0.0001; Table 2).
The on-treatment analysis demonstrated consistent results
(alirocumab 150Q4W 54.6%; placebo +5.1%; P<0.0001)
(Table S4). Data were comparable when either measured or
calculated LDL-C was used (Table S5).
At week 24, 63.9% of patients allocated to alirocumab
150Q4W achieved their LDL-C target levels versus 1.8% of
patients allocated to placebo (70.3% in the alirocumab
75Q2W group) (Table 2).
Across various patient subgroups the reductions in LDL-C
were similar to theprimary endpoint data atweek24 (FigureS3),
although patients with baseline free PCSK9 levels above the
median tended to see a greater reduction in LDL-C compared
with those with baseline levels below the median (Figure S3).
Considering concomitant therapies (ezetimibe and/or fenofi-
brate or diet alone), LDL-C reductions were consistent in the
alirocumab 150Q4W group at week 24 (Figure S3).
At week 24, significant (P<0.05) improvements in sec-
ondary efficacy endpoints including apolipoprotein B, non-
high-density lipoprotein cholesterol, and Lp(a) were observed
following treatment with alirocumab 150Q4W (Table 2).
Free PCSK9
In general, predictable dynamics were observed following
alirocumab administration, with free PCSK9 levels decreasing
concomitantly with LDL-C level reduction in the alirocumab
150Q4W group (or 75Q2W group) (Figure 2). Despite similar
baseline free PCSK9 levels, alirocumab-treated patients
receiving dose adjustment to 150 mg Q2W at week 12 had
a less pronounced decrease in mean free PCSK9 levels during
the first 12 weeks than those remaining on the initial
alirocumab dose (Figure 3; Figure S2). Following dose
adjustment, an additional reduction in mean free PCSK9
levels was observed with mean values close to 0, ranging from
1.6 to 3.6 ng/mL (Figure 3; Figure S2).
Device-Handling Questionnaire
At Weeks 0 and 12, 135 and 117 of all study participants
completed the device-handling questionnaire, respectively.
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Table 1. Baseline Characteristics (Randomized Population)
Placebo (n=58)
Alirocumab
75Q2W (n=116) 150Q4W (n=59)
Baseline demographics
Age, y, mean (SD) 63.1 (10.7) 62.5 (9.9) 64.2 (10.0)
Male, n (%) 31 (53.4) 69 (59.5) 30 (50.8)
Race, white, n (%) 56 (96.6) 108 (93.1) 55 (93.2)
Race, black or African American, n (%) 1 (1.7) 3 (2.6) 1 (1.7)
Ethnicity, Hispanic/Latino, n (%) 1 (1.7) 7 (6.0) 4 (6.8)
BMI, kg/m2, mean (SD) 28.5 (4.6) 29.4 (5.6) 28.2 (5.2)
HeFH, n (%) 5 (8.6) 15 (12.9) 9 (15.3)
Diagnosis of HeFH, n 5 15 9
By genotyping, n (%) 4 (80.0) 8 (53.3) 6 (66.7)
By WHO/Simon Broome criteria, n (%) 1 (20.0) 7 (46.7) 3 (33.3)
SAMS status, n (%)
SAMS 51 (87.9) 106 (91.4) 53 (89.8)
Non-SAMS 7 (12.1) 10 (8.6) 6 (10.2)
CHD history, n (%) 27 (46.6) 57 (49.1) 32 (54.2)
CHD risk equivalent*, n (%) 10 (17.2) 23 (19.8) 11 (18.6)
Hypertension, n (%) 37 (63.8) 69 (59.5) 36 (61.0)
Type 2 diabetes, n (%) 9 (15.5) 22 (19.0) 7 (11.9)
Categorization of cardiovascular risk, n (%)
Very-high cardiovascular risk 31 (53.4) 66 (56.9) 36 (61.0)
High cardiovascular risk 13 (22.4) 23 (19.8) 10 (16.9)
Moderate cardiovascular risk 14 (24.1) 27 (23.3) 13 (22.0)
Lipid medication, n (%)
Any LLT other than statins 41 (70.7) 82 (70.7) 42 (71.2)
Ezetimibe 35 (60.3) 70 (60.3) 35 (59.3)
Fenofibrate 3 (5.2) 12 (10.3) 5 (8.5)
Nutraceuticals 1 (1.7) 3 (2.6) 4 (6.8)
Diet alone† 20 (34.5) 35 (30.2) 20 (33.9)
Baseline lipid parameters, mg/dL, mean (SD)
LDL-C (calculated) 158.5 (47.3) 154.5 (44.6) 163.9 (69.1)
LDL-C (calculated), median (Q1:Q3) 148.5 (136.0:166.0) 146.0 (124.5:173.5) 148.0 (127.0:179.0)
LDL-C (measured) 156.6 (46.6) 154.1 (42.4) 167.5 (69.0)
Non-HDL-C 191.9 (51.0) 188.0 (49.9) 195.9 (76.4)
Total cholesterol 244.7 (50.8) 239.1 (50.2) 250.8 (75.7)
Apo B 120.3 (27.6) 120.2 (27.1) 126.5 (44.8)
Lp(a), median (Q1:Q3) 10.5 (4.0:31.0) 16.0 (5.0:46.0) 19.0 (5.0:41.0)
HDL-C 52.8 (16.6) 51.1 (15.1) 54.9 (13.4)
Fasting triglycerides, median (Q1:Q3) 154.5 (105.0:218.0) 147.5 (107.0:225.0) 145.0 (102.0:211.0)
Apo A1 151.0 (27.7) 150.5 (27.3) 154.8 (25.8)
75Q2W indicates 75 mg every 2 weeks (with possible dose adjustment to 150 mg every 2 weeks); 150Q4W, 150 mg every 4 weeks (with possible dose adjustment to 150 mg every
2 weeks); Apo, apolipoprotein; BMI, body mass index; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; HeFH, heterozygous familial hypercholesterolemia; LDL-C,
low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; Lp(a), lipoprotein(a); SAMS, statin-associated muscle symptoms; SD, standard deviation; WHO, World Health Organization.
*CHD risk equivalents were defined as abdominal aortic aneurysm, carotid artery occlusions >50% without symptoms, peripheral arterial disease, carotid endarterectomy or carotid artery
stent procedure, type 1 or 2 diabetes mellitus, with target organ damage, ischemic stroke, renal artery stenosis, and transient ischemic attack.
†Patients not taking fenofibrate or ezetimibe.
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Overall, the provided ratings at each time point were similar.
The overall experience in performing home self-injection was
rated as 6 or 7 (7=extremely satisfied) by 93% of the patients.
In addition, 92% of patients (n=125) were very satisfied with
the duration of injection (rating 6 or 7).
Safety
As described below and compared with placebo, alirocumab
was generally well tolerated at any dose regimen. The number
of patients with at least 1 TEAE was 45 (77.6%) in the
alirocumab 150Q4W group, 37 (63.8%) in the placebo group,
and 84 (73.0%) in the alirocumab 75Q2W group (Table 3).
Permanent discontinuations due to TEAEs occurred in 6.9%
and 3.4% of patients treated with alirocumab 150Q4W and
placebo, respectively (1.7% in the alirocumab 75Q2W group).
No deaths were reported during this study (Table 3). Serious
TEAEs were reported by 7 (12.1%) patients in the alirocumab
150Q4W group and 4 (6.9%) in the placebo group (6 [5.2%] in
the alirocumab 75Q2W group).
A list of TEAEs by preferred term occurring in ≥2% of
patients in either group is given in Table S6.
In regard to TEAEs of special interest, injection-site
reactions were experienced by 8 (13.8%) alirocumab
150Q4W-treated patients (vs 4 [3.5%] in alirocumab 75Q2W-
treated patients and 0 [0%] in the placebo group). The
intensity of all injection-site reactions was mild, except for 1
of moderate intensity in the alirocumab 75 mg Q2W group
(Table S6). Injection-site reactions occurred earlier and were
of longer duration in the alirocumab 150Q4W group; however,
none of the injection-site reactions led to treatment discon-
tinuation. No particular safety findings were detected for
neurological events. Neurocognitive events were reported by
1 patient in the alirocumab 150Q4W group (1.7%; aphasia)
and 1 patient in the alirocumab 75Q2W group (0.9%;
amnesia). These neurocognitive events were not serious and
did not lead to treatment discontinuation. A positively
adjudicated case of nonfatal myocardial infarction and of
ischemia-driven coronary revascularization were observed in 1
(1.7%) patient receiving alirocumab 150Q4W and in 1 (0.9%)
patient receiving alirocumab 75Q2W.
Three (2.7%) patients in the alirocumab 75Q2W group had
calculated LDL-C levels of <25 mg/dL on ≥2 consecutive
occasions (0 in the alirocumab 150Q4W group). No specific
safety concern was identified in these patients.
Antidrug Antibodies
The presence of antidrug antibodies had no observed effect
on LDL-C-lowering efficacy (Figure S4). A total of 1/109
(0.9%) patient in the alirocumab 75Q2W group developed a
low-titer, treatment-emergent persistent positive response for
the antialirocumab antibody assay (0 in the alirocumab
150Q4W group). Five patients in this study had positive
alirocumab-neutralizing activity: 1 patient (1/56; 1.8%) from
the alirocumab 150Q4W group and 4 patients (4/109; 3.7%)
from the alirocumab 75Q2W group.
Discussion
In ODYSSEY CHOICE II, patients with hypercholes-
terolemia not on statin therapy were treated with
A
B
Figure 2. Calculated LDL-C mean (SE) absolute values from
baseline (ITT analysis) (A) and free PCSK9 levels (B) over time (PK
analysis). DW 9 to 12 defined as percentage change in calculated
LDL-C from baseline to averaged values from weeks 9 to 12 vs
placebo in the ITT analysis; DW 24 defined as percentage change
in calculated LDL-C from baseline to week 24 vs placebo in the
ITT analysis. 75Q2W indicates 75 mg every 2 weeks (with
possible dose adjustment to 150 mg every 2 weeks); 150Q4W
indicates150 mg every 4 weeks (with possible dose adjustment
to 150 mg every 2 weeks); ITT, intent-to-treat; LDL-C, low-density
lipoprotein cholesterol; LS, least-squares; PCSK9, proprotein
convertase subtilisin/kexin type 9; SE, standard error.
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alirocumab 150Q4W, resulting in LDL-C reductions of
51.7% at week 24 (placebo +4.7%). ODYSSEY CHOICE II
was the first phase 3 study to use this alirocumab dose,
with results suggesting that 150Q4W may be convenient
for patients with hypercholesterolemia not on statin
therapy. The dose adjustment strategy would allow the
physician to modify the dose to Q2W if LDL-C targets
were not met.
The current study included weekly sample collection from
weeks 8 to 12, thereby allowing detailed assessment of LDL-C
levels as well as PCSK9 levels. In line with previous studies,17,18
alirocumab 150Q4W (and 75Q2W) led to a rapid and robust
reduction in mean free PCSK9 levels, which persisted for at
least 3 weeks (as shown between weeks 9 and 11) following
alirocumab 150Q4W administration. With administration of
alirocumab 75Q2W, mean free PCSK9 levels remained below
Table 2. Change From Baseline in Lipid End Points and Achievement of LDL-C Goals (ITT Analysis)
Placebo (n=57)
Alirocumab
75Q2W (n=115) 150Q4W (n=58)
Baseline, LS mean (SD) 156.7 (45.7) 155.1 (44.4) 164.4 (69.6)
Calculated LDL-C, LS mean (SE), mg/dL
Week 24 absolute LDL-C value 162.9 (3.7) 75.0 (2.6) 75.8 (3.7)
Absolute change from baseline to week 24 5.1 (3.7) 82.9 (2.6) 82.1 (3.7)
Percentage change from baseline to week 24 (primary end point) 4.7 (2.3)% 53.5 (1.6)% 51.7 (2.3)%
Percenaget difference vs placebo; P-value* 58.2 (2.8)%; <0.0001 56.4 (3.3)%; <0.0001†
Percentage change from baseline to week 12 3.2 (2.5)% 50.8 (1.7)% 41.7 (2.4)%
Percentage difference vs placebo; P-value* 54.0 (3.0)%; <0.0001 44.9 (3.5)%; <0.0001†
Percentage change from baseline to averaged weeks 9 to 12 3.2 (2.0)% 53.6 (1.4)% 52.3 (2.0)%
Percentage difference vs placebo; P-value* 56.7 (2.5)%; <0.0001 55.5 (2.9)%; <0.0001†
Percentage of patients achieving LDL-C goals <70 mg/dL or <100 g/dL at
week 24; P-value vs placebo
1.8% 70.3%; <0.0001 63.9%; <0.0001†
Percentage of patients achieving LDL-C <70 mg/dL at week 24 (LOCF);
P-value vs placebo
0 60.0%; <0.0001 50.0%; <0.0001
Percentage change from baseline to week 24 in other lipid parameters, LS mean (SE)
Apo B 7.5 (2.1)% 39.7 (1.5)% 38.9 (2.2)%
Percentage difference vs placebo; P-value* 47.2 (2.6)%; <0.0001 46.4 (3.0)%; <0.0001†
Non-HDL-C 4.8 (2.1)% 45.3 (1.5)% 44.2 (2.1)%
Percentage difference vs placebo; P-value* 50.1 (2.6)%; <0.0001 49.0 (3.0)%; <0.0001†
Total cholesterol 3.0 (1.6)% 34.0 (1.1)% 32.3 (1.6)%
Percentage difference vs placebo; P-value* 37.0 (2.0)%; <0.0001 35.3 (2.3)%; <0.0001†
Lp(a)‡ 4.1 (3.7)% 21.8 (2.6)% 15.5 (3.7)%
Percentage difference vs placebo; P-value* 25.9 (4.5)%; <0.0001 19.6 (5.2)%; 0.0002†
Fasting triglycerides‡ 1.1 (3.8)% 10.6 (2.7)% 9.2 (3.9)%
Percentage difference vs placebo; P-value* 11.8 (4.6)%; 0.0109 10.4 (5.4)%; 0.0556
HDL-C 2.4 (1.9)% 7.4 (1.4)% 7.7 (2.0)%
Percentage difference vs placebo; P-value* 9.8 (2.4)%; <0.0001 10.1 (2.8)%; 0.0003
Apo A1 3.4 (1.5)% 8.2 (1.1)% 10.0 (1.5)%
Percentage difference vs placebo; P-value* 4.8 (1.8)%; 0.0104 6.6 (2.1)%; 0.0025
75Q2W indicates 75 mg every 2 weeks (with possible dose adjustment to 150 mg every 2 weeks); 150Q4W, 150 mg every 4 weeks (with possible dose adjustment to 150 mg every
2 weeks); Apo, apolipoprotein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LOCF, last observation carried forward; Lp(a), lipoprotein(a); LS, least
squares; SD, standard deviation; SE, standard error.
*P-values are for the comparison with placebo.
†P-value is statistically significant according to the fixed hierarchical approach used to ensure a strong control of the overall type-I error rate at the 0.05 level (only applicable to comparison
of alirocumab 150Q4W arm vs placebo).
‡Combined estimate for adjusted mean (SE).
DOI: 10.1161/JAHA.116.003421 Journal of the American Heart Association 8
Alirocumab 150 mg Q4W: ODYSSEY CHOICE II Stroes et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
ay 22, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
25% of baseline levels throughout the 4-week period. However,
in the 150Q4W group, there was a modest increase of free
PCSK9 levels between weeks 11 and 12 that coincided with a
small tailing off of LDL-C efficacy.
At week 12, before possible dose modification, when
patients remained on either alirocumab 150 mg Q4W or
75 mg Q2W, 45.9% and 60.7% of patients, respectively,
achieved their predefined LDL-C target levels despite none of
them being on a statin.
The dose adjustment at week 12 (based on LDL-C values at
week 8) resulted in an additional reduction in LDL-C of 34.4%
(alirocumab 150Q4W) and 15.8% (alirocumab 75Q2W) from
weeks 12 to 24, corresponding to an incremental benefit of
~19% and ~11% compared with baseline, respectively. At
week 24, after possible dose modification, 63.9% of patients
in the alirocumab 150Q4W group had achieved their prede-
fined LDL-C targets (alirocumab 75Q2W group 70.3%). Higher
LDL-C levels at baseline were associated with dose adjust-
ment at week 12, with duration of effect across the dosing
interval also being a contributory factor toward some patients
receiving a dose adjustment.
At week 24, LDL-C reductions were 51.7% in the
alirocumab 150Q4W arm and 53.5% in the 75Q2W arm.
Importantly, alirocumab 75Q2W used as a calibrator arm
demonstrated results that are consistent with LDL-C-
lowering efficacy and with safety data of alirocumab used
as add-on or monotherapy in previously published studies
from the ODYSSEY clinical trials program.12-14 Significant
reductions in LDL-C levels have also been seen with Q4W
dosing of another PCSK9 inhibitor, evolocumab, in statin-
A
B
Figure 3. Impact of dosing regimen adjustment on LDL-C levels
(ITT analysis*) (A) and free PCSK9 levels (B) in patients in the
150 mg Q4W alirocumab cohort: time profile from baseline to
Week 24 (PK analysis*). *Patients who received dose adjustment
at Week 12 and had at least 1 subsequent injection. LDL-C
indicates low-density lipoprotein cholesterol; PCSK9, proprotein
convertase subtilisin/kexin type 9; Q2W, every 2 weeks; Q4W,
every 4 weeks; SE, standard error.
Table 3. Adverse Events and Safety Laboratory Values
(Safety Population)
Placebo
(n=58)
Alirocumab
75Q2W
(n=115)
150Q4W
(n=58)
TEAEs, n (%) 37 (63.8) 84 (73.0) 45 (77.6)
Treatment-emergent SAEs,
n (%)
4 (6.9) 6 (5.2) 7 (12.1)
TEAEs leading to death, n (%) 0 0 0
TEAEs leading to
discontinuation, n (%)
2 (3.4) 2 (1.7) 4 (6.9)
Safety terms of interest, n (%)
Adjudicated cardiovascular
events*
0 1 (0.9) 1 (1.7)
General allergic reactions 4 (6.9) 5 (4.3) 6 (10.3)
General allergic serious
TEAE (CMQ)
0 0 0
Neurological TEAE 2 (3.4) 5 (4.3) 4 (6.9)
Neurocognitive disorders 0 1 (0.9%) 1 (1.7%)
Laboratory parameters†, n (%)
Alanine aminotransferase
>3 times ULN
0/58 1/115 (0.9) 0/58
Aspartate aminotransferase
>3 times ULN
0/58 0/115 0/58
Creatine kinase >3 times
ULN
1/57 (1.8) 8/115 (7.0) 4/57 (7.0)
75Q2W indicates 75 mg every 2 weeks (with possible dose adjustment to 150 mg every
2 weeks); 150Q4W, 150 mg every 4 weeks (with possible dose adjustment to 150 mg
every 2 weeks); CHD, coronary heart disease; CMQ, Custom Medical Dictionary of
Regulatory Activities Query; SAE, serious adverse event; TEAE, treatment-emergent
adverse events; ULN, upper limit of normal.
*Includes CHD death, nonfatal myocardial infarction, fatal and nonfatal ischemic stroke,
unstable angina requiring hospitalization, congestive heart failure requiring
hospitalization, and ischemia-driven coronary revascularization procedure.
†Regardless of baseline status.
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intolerant patients.8 In that study, mean percentage reduc-
tions from baseline in LDL-C at week 12 were 56.1% with
evolocumab 140 mg Q2W and 52.6% with evolocumab
420 mg Q4W. The effectiveness of alirocumab 300 mg
Q4W has also been investigated in patients receiving
concomitant statin therapy in the ODYSSEY CHOICE I
study. The changes in LDL-C from baseline to week 24
were 58.8% (placebo 0.1%) with alirocumab 300 mg
Q4W (with possible dose adjustment to 150 mg Q2W at
week 12) in patients on statin, and at week 12, only 19.3%
of those patients required dose adjustment.24
Despite the fact that 90.1% of patients included in this
study had a history of experiencing intolerable SAMS on
multiple statins, we observed a low rate of muscle-related
symptoms with alirocumab treatment. These data support
the concept that LDL-C lowering per se is not a pivotal factor
in SAMS and/or causation of myopathy.7 It should be noted
that patients with perceived SAMS not utilizing statin therapy
are unlikely to experience the degree of LDL-C lowering
needed to reduce cardiovascular risk with other traditional
lipid-lowering therapies.7 Causality of SAMS is debated, with
randomized, blinded, and placebo-controlled trials often
reporting similar rates of muscle AEs between statin and
placebo arms and with lower rates of muscle symptoms
compared with observational studies.25 These findings imply
that perceived SAMS, besides potential pharmacological and
pharmacogenetic factors, are also likely to include a
behavioral component from the expectation that statins can
cause muscle symptoms.7,25 In support, many patients who
discontinue statins due to SAMS can be successfully
rechallenged.7,10,26
Injection-site reactions were reported at a higher rate in
patients receiving 150Q4W alirocumab versus comparator
arms. Here, it should be emphasized that the number of
patients was relatively small in this treatment arm. Further-
more, all injection-site reactions in the 150Q4W arm were of
mild intensity and of limited duration. Because of the sample
size per group in this study, small percentage differences
between treatment groups may not be clinically meaningful,
as similar trends were not observed in previously published
larger alirocumab studies.13,14,27
Conclusions
Overall, these data suggest that alirocumab 150Q4W may
provide an additional option to further optimize the treatment
of patients with SAMS not receiving statin treatment.
However, this dosing strategy may not provide adequate
LDL-C reduction in all patients, for example, those receiving
concomitant statin or those with higher baseline LDL-C levels.
In these patients, either a higher dose of alirocumab 300Q4W
or alirocumab 75 mg Q2W (with possible dose adjustment to
150 mg Q2W) is likely to be preferred.
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Supplementary Materials 
CHOICE II Investigators 
Principal Investigators 
Australia: K. Kostner (Woolloongabba, Qld); S. Lehman (Ashford, SA); G. Watts 
(Perth, WA)  
Belgium: O. Descamps (Haine-Saint-Paul); L. Gheyle (Antwerpen); C. Mathieu 
(Leuven) 
Canada: J. Bergeron (Quebec); T. Elliott (Vancouver); D. Gaudet (Chicoutimi);  
G. Girard (Sherbrooke); A. Gupta (Toronto); G. Hoag (Victoria);  
Denmark: J. Hove (Hvidovre); J. Jeppesen (Glostrup); J.H. Kjærulf (Aarhus N);  
K. Klarlund (Køge); K.K. Thomsen (Esbjerg) 
Netherlands: D.C.G. Basart (Hoorn); A. Kooy (Hoogeveen); A. Liem (Rotterdam);  
J E.S.G. Stroes (Amsterdam); H. Swart (Sneek); R. Troquay (Venlo); J. Van Het Hof-
Wiersma (Hoorn); P. Viergever (Den Helder); F. Visseren (Utrecht)  
New Zealand: R.N. Doughty (Auckland); R. Scott (Canterbury) 
Spain: C. Calvo (La Coruña); F. Civeira (Zaragoza); J.L. Díaz-Díaz (La Coruña);  
F. Fuentes (Córdoba); B. Gil-Extremera (Granada); C. Jericó (Barcelona); L. Matas 
Pericas (Barcelona); J.D. Mediavilla Garcia (Granada)  
United States: D.E. Bolster (Summerville, NC); J. Guyton (Durham, NC); M. Koren 
(Jacksonville, FL); N. Lepor (Beverly Hills, CA); M. El Shahawy (Sarasota, FL);  
G. Vardi (St. Louis, MO); D. Weinstein (Atlantis, FL); K. Zuzarte (Fall River, MA)  
 by guest on M
ay 22, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
   
Page 2 
Steering Committee 
Chairman: Henry Ginsberg (Irving Institute for Clinical and Translational Research, 
Columbia University New York, NY, USA). Members: Jennifer G. Robinson (The 
University of Iowa, Iowa City, IA, USA); Daniel J. Rader (Institute for Translational 
Medicine and Therapeutics, University of Pennsylvania School of Medicine 
Philadelphia, PA, USA); Christopher P. Cannon (Senior Investigator, TIMI Study 
Group; Professor of Medicine, Harvard Medical School Cardiovascular Division, 
Brigham and Women's Hospital, Boston, MA, USA); Helen Colhoun (Clinical Centre, 
University of Dundee, Ninewells Hospital & Medical School, Dundee, UK);  
John J.P. Kastelein (Academic Medical Center University of Amsterdam, 
Amsterdam, The Netherlands); Michel Farnier (Le Point Médical, Département 
d’Endocrinologie et de Lipidologie, Dijon, France); Yong Huo (Peking University First 
Hospital, Beijing, China).  
Data Monitoring Committee 
DMC Chairman: Anders Olsson (Bromma, Sweden). Members: David Waters, MD 
(Division of Cardiology, San Francisco General Hospital, San Francisco, CA, USA); 
Dominique Larrey (Hôpital Saint-Eloi Service d'hépato-gastro-entérologie, 
Montpellier, France); Robert S. Rosenson (Director, Cardiometabolic Disorders, 
Mount Sinai Heart; Professor of Medicine, Mount Sinai School of Medicine, New 
York, NY, USA); Peter A. Patriarca (Biologics Consulting Group, Inc., Alexandria, 
VA, USA); Geert Molenberghs, Biostatistician (Center for Statistics [CenStat], 
Diepenbeek, Belgium).  
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Clinical Events Committee (Reviewers) 
Clinical Events Committee, Duke Clinical Research Institute, Durham, NC, USA; 
Pierluigi Tricoci, CEC Principal Investigator, Cardiology; Kenneth W. Mahaffey, CEC 
Director, Cardiology; Renato D. Lopes, Cardiology; Bimal R. Shah, Cardiology; 
Rajendra H. Mehta, Cardiology; Matthew T. Roe, Cardiology; Zubin Eapen, 
Cardiology; Luciana Armaganijan, Cardiology; Adriana Bertolami, Cardiology; Sergio 
Leonardi, Cardiology; Bradley J. Kolls, Neurology; J. Dedrick Jordan, Neurology; 
Grégory Ducrocq, Cardiology; Etienne Puymirat, Cardiology; Robin Mathews, 
Cardiology. 
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Safety Events of Interest 
The selection of preferred terms for the AE categories was based on Standard 
Medical Dictionary for Regulatory Activities (MedDRA) queries (SMQs) or Custom 
Standard MedDRA queries. 
The safety events of interest and other potentially significant AEs were identified 
as follows for analysis purposes: 
• Local injection site reactions, selected using the e-CRF-specific tick-box on the AE 
page 
• Allergic events 
– General allergic events, selected using the SMQ “hypersensitivity” (broad and 
narrow) excluding the following preferred terms (PTs) linked to local injection 
site reactions (“infusion site dermatitis,” “infusion site hypersensitivity,” “infusion 
site rash,” “infusion site urticaria,” “injection site dermatitis,” “injection site 
hypersensitivity,” “injection site rash,” “injection site urticaria”, and “injection site 
vasculitis”) 
– General allergic events and local allergic reactions at investigational medicinal 
product (IMP) injection site based on the above selection for general allergic 
event and on the following selection of PTs from the symptoms complementary 
form for local injection site reaction (“injection site dermatitis,” “injection site 
hypersensitivity,” “injection site edema,” “injection site rash,” “injection site 
urticaria,” “injection site eczema,” “injection site vasculitis,” “injection site 
swelling,” “infusion site dermatitis,” “infusion site hypersensitivity,” “infusion site 
edema,” “infusion site rash,” “infusion site urticaria,” and “infusion site swelling”) 
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• ALT ≥3 × upper limit of normal (ULN) (if baseline ALT <ULN) or ALT ≥2 times the 
baseline value (if baseline ALT ≥ULN), selected using laboratory data 
• Hemolytic anemia, selected using e-CRF-specific tick-box on the AE page and 
confirmed final diagnosis provided in the AE complementary form 
• Neurologic events 
– Neurologic event, selected using SMQs “demyelination” (broad and narrow), 
“peripheral neuropathy” (broad and narrow), and “Guillain-Barre syndrome” 
(broad and narrow) excluding the following PTs: “acute respiratory distress 
syndrome,” “asthenia,” “respiratory arrest”, and “respiratory failure”; 
• Neurocognitive events were analyzed based on 2 different groupings 
– Sponsor CMQ grouping: neurocognitive events were selected using a CMQ, 
based on the following 5 high-level group terms (HLGTs): “deliria (including 
confusion),” “cognitive and attention disorders and disturbances,” “dementia 
and amnestic conditions,” “disturbances in thinking and perception,” and 
“mental impairment disorders.” 
– CMQ grouping requested by a health authority: This grouping included the 
following terms: PT “amnesia,” PT “amnestic disorder,” PT “anterograde 
amnesia,” PT “behavioral and psychiatric symptoms of dementia,” PT ”change 
in sustained attention,” lowest-level term “cognitive deterioration,” PT “cognitive 
disorder,” lowest-level term “confusion,” lowest-level term “confusion 
aggravated,” PT “confusional state,” PT “delirium,” PT “dementia,” PT 
“dementia Alzheimer's type,” lowest-level term “dementia not otherwise 
specified (NOS),” lowest-level term “dementia NOS aggravated,” lowest-level 
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term “dementia of the Alzheimer's type NOS,” PT “dementia with Lewy bodies,” 
PT “disorientation,” PT “disturbance in attention,” PT “executive dysfunction,” 
PT “frontotemporal dementia,” lowest-level term “global amnesia,” PT “illogical 
thinking,” PT “impaired reasoning,” PT “incoherent,” PT “judgement impaired,” 
PT “memory impairment,” PT “mental impairment,” lowest-level term “mental 
impairment NOS,” lowest-level term “mental state abnormal aggravated,” PT 
“mental status changes,” PT “mini mental status examination abnormal,” PT 
“presenile dementia,” PT “retrograde amnesia,” PT “senile dementia,” lowest-
level term “senile dementia NOS,” lowest-level term “short-term memory loss,” 
PT “thinking abnormal,” lowest-level term “thinking slowed,” PT “transient global 
amnesia,” PT “vascular dementia.” 
• Ophthalmologic events selected using the SMQs “optic nerve disorders” (broad 
and narrow), “retinal disorders” (narrow), and “corneal disorders” (narrow) 
• Overdose with IMP (symptomatic or asymptomatic), selected using high-level term 
(HLT) “Overdose” and the tick box “Overdose with IMP” in the AE complementary 
e-CRF form 
• Pregnancy (female patients or male patient’s partners) selected using appropriate 
MedDRA codes. 
Analysis of Other Potentially Significant AEs 
Additional grouping of AEs was identified as follows for analysis purposes: 
• Hepatic disorder events using SMQ “hepatic disorder” 
• Diabetes mellitus or diabetic complications using HLGT “diabetes complications,” 
HLT “diabetes mellitus,” HLT “carbohydrate tolerance analyses (including 
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diabetes)” excluding the PT “blood glucose decreased” but including the PT 
“hyperglycemia” and the microvascular complications, which pertain to the 
secondary system organ class (SOC) included in the defined HLGT/HLTs, 
secondary SOCs in the MedDRA coding system. 
Analysis of Cardiovascular Events 
Suspected cardiovascular events and all deaths that occurred from randomization 
until the follow-up visit were to be submitted to the Clinical Events Committee (CEC) 
for adjudication. An analysis of adjudicated cardiovascular events was performed. 
Adjudicated cardiovascular events included all cardiovascular AEs and procedures 
positively adjudicated as defined in the CEC charter 
• Coronary heart disease death 
• Non-fatal myocardial infarction 
• Fatal and non-fatal ischemic stroke 
• Unstable angina requiring hospitalization (of note, a strict definition was applied 
for this end point, which was only considered when there was definite evidence of 
progression of the ischemic condition) 
• Congestive heart failure requiring hospitalization 
• Ischemia-driven coronary revascularization procedure. 
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Supplemental Material 
Table S1. Exclusion Criteria 
 Exclusion criteria 
1 Patients defined as statin intolerant and at very high CV risk with LDL-C <70 mg/dL  
(1.81 mmol/L) at the screening visit (Week –3, Visit 1) 
2 Patients defined as statin intolerant and high or moderate CV risk with LDL-C <100 mg/dL  
(< 2.59 mmol/L) at the screening visit (Week –3, Visit 1) 
3 Patients not fulfilling the statin intolerant definition and who are at moderate CV risk with  
LDL-C < 100 mg/dL (<2.59 mmol/L) at the screening visit (Week –3, Visit 1) 
4 Patients with LDL-C ≥160 mg/dL (≥ 4.1 mmol/L) at the screening visit (Week –3, Visit 1) if 
receiving treatment with diet only, whatever the statin intolerance status or if non-fulfilling 
statin intolerance definition at moderate CV risk and treated with ezetimibe or fenofibrate 
5 Patients with a 10-year fatal CVD risk SCORE <1% (ESC/EAS 2011) at the screening visit 
(Week –3, Visit 1) 
6 Patients newly diagnosed (within 3 months prior to randomization visit [Week 0]) or poorly 
controlled (HbA1c >9%) diabetes 
7 Patients with use of statin, red yeast rice products, niacin, or bile acid sequestrant within 4 
weeks of the screening visit (Week –3) or between screening and randomization visits 
8 Patients not on a stable dose of ezetimibe or fenofibrate for at least 4 weeks prior to the 
screening visit (Week –3, Visit 1) or between screening and randomization visits 
9 Patients with use of fibrates, other than fenofibrate, within 4 weeks of the screening visit 
(Week –3, Visit 1) or between screening and randomization visits 
10 Patients with use of nutraceuticals or over-the-counter therapies known to affect lipids, at a 
dose/amount that has not been stable for at least 4 weeks, prior to the screening visit  
(Week –3, Visit 1) or between screening and randomization visits 
11 Patients planned to undergo scheduled PCI, CABG, or carotid or peripheral revascularization 
during the study 
12 Patients with systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at 
screening (Week –3, Visit 1) and/or randomization (Week 0) visits 
13 Patients with history of New York Heart Association Appendix B Class III or IV heart failure 
within the past 12 months 
14 Patients with history of a myocardial infarction, unstable angina leading to hospitalization, 
CABG, PCI, uncontrolled cardiac arrhythmia, carotid surgery or stenting, stroke, transient 
ischemic attack, carotid revascularization, endovascular procedure, or surgical intervention for 
peripheral vascular disease within 3 months prior to the screening visit (Week –3, Visit 1) 
15 Patients with known history of hemorrhagic stroke 
16 Patients aged <18 years or legal age of majority at the screening visit (Week –3, Visit 1) 
whichever is older 
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17 Patients not previously instructed on a cholesterol-lowering diet prior to the screening visit 
(Week –3, Visit 1) 
18 Presence of any clinically significant uncontrolled endocrine disease known to influence serum 
lipids or lipoproteins (note: patients on thyroid replacement therapy could be included if the 
dosage of thyroxin has been stable for at least 12 weeks prior to screening and TSH level is 
within the normal range of the central laboratory at the screening visit) 
19 Patients with history of bariatric surgery within 12 months prior to the screening visit (Week –3, 
Visit 1) 
20 Patients with unstable weight defined by a variation >5 kg within 2 months prior to the 
screening visit (Week –3, Visit 1) 
21 Patients with known history of homozygous familial hypercholesterolemia 
22 Patients with known history of loss of function of PCSK9 (i.e., genetic mutation or sequence 
variation) 
23 Patients with use of systemic corticosteroids, unless used as replacement therapy for 
pituitary/adrenal disease with a stable regimen for at least 6 weeks prior to randomization 
(note: topical, intra-articular, nasal, inhaled, and ophthalmic steroid therapies were not 
considered as “systemic” and were allowed) 
24 Patients with history of cancer within the past 5 years, except for adequately treated basal cell 
skin cancer, squamous cell skin cancer, or in situ cervical cancer 
25 Patients with known history of a positive HIV test 
26 Patients who have taken any active investigational drugs within 1 month or 5 half-lives, 
whichever is longer 
27 Patients who have been previously treated with at least 1 dose of alirocumab or any other 
anti-PCSK9 monoclonal antibody in other clinical trials 
28 Patients with use of continuous hormone replacement therapy unless the regimen has been 
stable in the past 6 weeks prior to the screening visit (Week –3) and no plans to change the 
regimen during the study 
29 Patients who withdraw consent during the screening period (patient who is not willing to 
continue or fails to return) 
30 Conditions/situations or laboratory findings, such as: 
Any clinically significant abnormality identified at the time of screening that in the judgment 
of the investigator or any sub-investigator would preclude safe completion of the study or 
constrain end points assessment such as major systemic diseases, patients with short life 
expectancy 
Patients considered by the investigator or any sub-investigator as inappropriate for this 
study for any reason, e.g.: 
Those deemed unable to meet specific protocol requirements, such as scheduled visits 
Those deemed unable to administer or tolerate long-term injections as per the patient or 
the investigator 
Investigator or any sub-investigator, pharmacist, study coordinator, other study staff or 
relative thereof directly involved in the conduct of the protocol, etc. 
Presence of any other conditions (e.g., geographic, social) actual or anticipated, that the 
investigator feels would restrict or limit the patient’s participation for the duration of the 
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study 
31 Laboratory findings during the screening period (not including randomization labs): 
Positive test for hepatitis B surface antigen or hepatitis C antibody 
Positive serum or urine pregnancy (including Week 0) test in women of childbearing 
potential 
Triglycerides >400 mg/dL (>4.52 mmol/L) (1 repeat lab was allowed) 
eGFR <30 mL/min/1.73 m2 according to 4-variable MDRD study equation (calculated by 
central lab) 
ALT or AST >3 x ULN (1 repeat lab is allowed) 
CPK >3 x ULN (1 repeat lab is allowed) 
TSH <LLN or >ULN 
32 Patients with known hypersensitivity to monoclonal antibody or any component of the drug 
product 
33 Pregnant or breast-feeding women. Women of childbearing potential not protected by highly-
effective method(s) of birth control (as defined in the informed consent form and/or in a local 
protocol addendum) and/or who are unwilling or unable to be tested for pregnancy. (Note: 
women of childbearing potential must have a confirmed negative pregnancy test at screening 
and randomization visits. They must use an effective contraceptive method throughout the 
entire duration of the study treatment, and for 10 weeks after the last intake of IMP, and agree 
to repeat urine pregnancy test at designated visits. The applied methods of contraception 
have to meet the criteria for a highly effective method of birth control according to the 
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use. M3(R2): guidance on nonclinical safety studies for the 
conduct of human clinical trials and marketing authorization for pharmaceuticals. ICH. 2009 
Jun:1-25. Postmenopausal women must be amenorrheic for at least 12 months. 
34 Significant protocol deviation in the double-blind period based on the Investigator judgment, 
such as non-compliance by the patient 
35 Any patient who experienced an adverse event leading to permanent discontinuation from IMP 
during the double-blind period 
36 Patients having any new condition or worsening of existing condition which in the opinion of 
the investigator would make the patient unsuitable for enrollment, or could interfere with the 
patient participating in or completing the study 
37 Patients with known hypersensitivity to monoclonal antibody or any component of the drug 
product 
38 Patients with positive pregnancy test at last visit of the double-blind period (Week 24, Visit 11) 
39 Women of childbearing potential not willing to continue highly-effective method(s) of birth 
control (as defined in the informed consent form and/or in a local protocol addendum) and/or 
who are unwilling or unable to be tested for pregnancy 
ALT indicates alanine aminotransferase; AST, aspartate transferase; CABG, coronary artery bypass graft; CPK, 
creatine phosphokinase; CV, cardiovascular; CVD, cardiovascular disease; EAS, European Atherosclerosis 
Society; eGFR, estimated glomerular filtration rate; ESC, European Society of Cardiology; HbA1c, glycated 
hemoglobin; IMP, investigational medicinal product; LDL-C, low-density lipoprotein cholesterol; LLN, lower limit of 
normal; MDRD, modification of diet in renal disease; PCI, percutaneous coronary intervention; PCSK9, proprotein 
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convertase subtilisin/kexin type 9; SCORE, Systematic COronary Risk Evaluation; TSH, thyroid-stimulating 
hormone; ULN, upper limit of normal. 
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Table S2. Reasons for Not Completing the Study Treatment Period 
(Randomized Population) 
n (%) Placebo (n=58) 
Alirocumab 
75Q2W 
(n=116) 
150Q4W 
(n=59) 
Discontinued due to adverse event 2 (3.4) 2 (1.7) 5 (8.5) 
Discontinued due to poor 
compliance to protocol 0 2 (1.7) 1 (1.7) 
Life events made continuing 
too difficult 0 1 (0.9) 0 
Other reasons 0 1 (0.9) 1 (1.7) 
Other reasons 2 (3.4) 4 (3.4) 2 (3.4) 
Physician decision 0 1 (0.9) 0 
Other 2 (3.4) 3 (2.6) 2 (3.4) 
75Q2W indicates 75 mg every 2 weeks (with possible dose adjustment to 150 mg every 2 weeks); 150Q4W, 150 
mg every 4 weeks (with possible dose adjustment to 150 mg every 2 weeks). 
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Table S3. Baseline Characteristics According to Dose Adjustment Status 
(Safety Population*) 
 
Alirocumab 150Q4W Alirocumab 75 mg Q2W 
Patients 
remaining on  
150 mg Q4W 
(n=27) 
Patients with 
dose adjustment 
to 150 mg Q2W† 
(n=26) 
Patients 
remaining on  
75 mg Q2W 
(n=71) 
Patients with dose 
adjustment to 150 mg 
Q2W† 
(n=40) 
Baseline 
demographics     
Age, y, mean 
(SD) 64.0 (10.3) 62.7 (9.0) 64.3 (9.1) 59.5 (11.0) 
Male, n (%) 17 (63.0) 11 (42.3) 42 (59.2) 24 (60.0) 
Race, White, n 
(%) 25 (92.6) 25 (96.2) 64 (90.1) 39 (97.5) 
Race, Black or 
African-
American, % 
(n) 
0 0 2 (2.8) 1 (2.5) 
Ethnicity, 
Hispanic/Latino, 
n (%) 
1 (3.7) 2 (7.7) 5 (7.0) 2 (5.0) 
BMI, kg/m2, 
mean (SD) 27.3 (4.4) 28.9 (6.1) 28.8 (5.2) 30.5 (6.5) 
HeFH, n (%) 1 (3.7) 7 (26.9) 1 (1.4) 14 (35.0) 
Diagnosis of 
HeFH, n 1 7 1 14 
By 
genotyping, 
n (%) 
0 6 (85.7) 0 8 (57.1) 
By 
WHO/Simon 
Broome 
criteria, n 
(%) 
1 (100) 1 (14.3) 1 (100) 6 (42.9) 
Free PSCK9‡, 
ng/mL, mean 
(SD) 
198.9 (72.6) 199.7 (66.8) 227.7 (83.5) 208.0 (69.4) 
Total PSCK9‡, 
ng/mL, mean 
(SD) 
469.0 (159.0) 562.3 (167.1) 504.0 (178.3) 523.9 (185.3) 
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LDL-C 
(calculated) , 
mean (SD) 
130.3 (25.3) 197.5 (86.9) 137.3 (26.0) 188.6 (52.2) 
≥70 to <100 
mg/dL, n 
(%) 
4 (14.8) 0 4 (5.6) 0 
≥100 to 
<130 mg/dL, 
n (%)  
10 (37.0) 1 (3.8) 26 (36.6) 4 (10.0) 
≥130 to 
<160 mg/dL, 
n (%)  
10 (37.0) 9 (34.6) 29 (40.8) 11 (27.5) 
≥160 to 
<190 mg/dL, 
n (%)  
3 (11.1) 8 (30.8) 8 (11.3) 8 (20.0) 
≥190 mg/dL, 
n (%) 0 8 (30.8) 4 (5.6) 17 (42.5) 
LDL-C 
(calculated), 
median 
(Q1:Q3) 
127.0 
(113.0:148.0) 
178.0 
(143.0:212.0) 
134.0 
(122.0:151.0) 
179.5  
(146.5:223.0) 
LDL-C 
(measured), 
mean (SD) 
133.4 (26.7) 199.5 (85.7) 136.9 (24.4) 187.1 (50.0) 
Non-HDL-C, 
mean (SD) 160.0 (32.8) 232.8 (95.3) 171.0 (34.0) 222.7 (56.9) 
Total 
cholesterol, 
mean (SD) 
213.0 (31.9) 288.9 (92.5) 222.7 (34.3) 272.8 (58.0) 
Apo B, mean 
(SD) 105.4 (21.6) 145.1 (53.6) 110.9 (18.7) 138.5 (31.4) 
Lp(a), median 
(Q1:Q3) 7.0 (4.0:41.0) 21.5 (9.0:42.0) 
16.0 
(6.0:41.0) 15.0 (3.0:72.0) 
<30 mg/dL, 
n (%) 20 (74.1) 16 (61.5) 46 (64.8) 22 (56.4) 
≥30 to <50 
mg/dL, n 
(%) 
3 (11.1) 4 (15.4) 14 (19.7) 5 (12.8) 
≥50 mg/dL, 
n (%) 4 (14.8) 6 (23.1) 11 (15.5) 12 (30.8) 
HDL-C, mean 
(SD) 52.9 (13.6) 56.1 (13.7) 51.7 (14.9) 50.1 (16.2) 
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<40 mg/dL, 
n (%) 4 (14.8) 2 (7.7) 18 (25.4) 11 (27.5) 
≥40 mg/dL, 
n (%) 23 (85.2) 24 (92.3) 53 (74.6) 29 (72.5) 
Fasting 
triglycerides, 
median 
(Q1:Q3) 
117.0  
(95.0:205.0) 
156.0 
(115.0:234.0) 
137.0 
(96.0:228.0) 164.0 (123.0:226.0) 
<150 mg/dL, 
n (%) 16 (59.3) 12 (46.2) 37 (52.1) 16 (40.0) 
≥150 to 
<200 mg/dL, 
n (%) 
3 (11.1) 4 (15.4) 9 (12.7) 11 (27.5) 
≥200 mg/dL, 
n (%) 8 (29.6) 10 (38.5) 25 (35.2) 13 (32.5) 
Apo A1, mean 
(SD) 147.9 (24.4) 157.7 (25.5) 152.6 (26.8) 146.0 (28.1) 
*Patients who had at least 1 subsequent injection. 
†Patients who received dose adjustment at Week 12 and had at least 1 subsequent injection. 
‡Including patients from the pharmacokinetic population (patients with ≥1 injection post-IVRS transaction at Week 
12). 
150Q4W indicates 150 mg every 4 weeks (with possible dose adjustment to 150 mg every 2 weeks); Apo, 
apolipoprotein; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; HeFH, heterozygous familial 
hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); PCSK9, proprotein 
convertase subtilisin/kexin type 9; Q2W, every 2 weeks; Q4W, every 4 weeks; SD, standard deviation; WHO, 
World Health Organization. 
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Table S4. Percent Change from Baseline in Calculated LDL-C at Week 24: 
Mixed-Effect Model with Repeated Measures (On-Treatment Analysis – 
Modified ITT Population)  
 
Placebo (n=56) 
Alirocumab 
75Q2W 
(n=115) 
150Q4W 
(n=57) 
Baseline, mean (SD), mg/dL 156.0 (45.8) 155.1 (44.4) 165.0 (70.1) 
LS mean (SE) change from 
baseline to Week 24 in measured 
LDL-C, %  
5.1 (2.1) –55.3 (1.5) –54.6 (2.1) 
LS mean difference (SE) 
versus placebo  –60.4 (2.6) –59.7 (3.0) 
95% confidence interval  (–65.4 to –55.4) (–65.6 to –53.8) 
P-value versus placebo  <0.0001 <0.0001* 
*P-value is statistically significant according to the fixed hierarchical approach used to ensure a strong control of 
the overall type-I error rate at the 0.05 level (only applicable to comparison of alirocumab 150Q4W arm versus 
placebo).  
75Q2W indicates 75 mg every 2 weeks (with possible dose adjustment to 150 mg every 2 weeks); 150Q4W, 150 
mg every 4 weeks (with possible dose adjustment to 150 mg every 2 weeks); LDL-C, low-density lipoprotein 
cholesterol; LS, least-squares; SD standard deviation; SE, standard error 
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Table S5. Percent Change from Baseline in Measured LDL-C at Week 24: 
Analysis of Covariance – Complete Case Analysis (ITT Analysis – ITT 
Population)  
 
Placebo (n=57) 
Alirocumab 
75Q2W 
(n=115) 
150Q4W 
(n=58) 
Number of patients with measured 
LDL-C values available  54 108 53 
Baseline, mean (SD), mg/dL 158.1 (46.9) 154.5 (43.4) 168.4 (71.9) 
LS mean (SE) change from 
baseline to Week 24 in measured 
LDL-C, %  
3.7 (2.2) –50.4 (1.6) –50.7 (2.3) 
LS mean difference (SE) 
versus placebo  –54.1 (2.7) –54.4 (3.2) 
95% confidence interval  (–59.5 to –48.7) (–60.7 to –48.1) 
P-value versus placebo  <0.0001 <0.0001 
75Q2W indicates 75 mg every 2 weeks (with possible dose adjustment to 150 mg every 2 weeks); 150Q4W, 150 
mg every 4 weeks (with possible dose adjustment to 150 mg every 2 weeks); ITT, intention-to-treat; LDL-C, low-
density lipoprotein cholesterol; LS, least-squares; SD, standard error; SE, standard error 
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Table S6. Adverse Events by Preferred Term Occurring in ≥2% of Patients in 
Either Group (Safety Population)  
 
Placebo (n=58) 
Alirocumab 
75Q2W 
(n=115) 
150Q4W 
(n=58) 
TEAEs occurring in ≥2% 
patients in either group, n (%)    
Infections and infestations 13 (22.4) 32 (27.8) 22 (37.9) 
Nasopharyngitis 3 (5.2) 10 (8.7) 5 (8.6) 
Urinary tract infection 1 (1.7) 4 (3.5) 4 (6.9) 
Upper respiratory tract 
infection 4 (6.9) 4 (3.5) 3 (5.2) 
Influenza 0 3 (2.6) 1 (1.7) 
Psychiatric disorders 0 9 (7.8) 2 (3.4) 
Insomnia 0 3 (2.6) 0 
Nervous system disorders 8 (13.8) 17 (14.8) 12 (20.7) 
Headache 3 (5.2) 10 (8.7) 5 (8.6) 
Dizziness 4 (6.9) 1 (0.9) 4 (6.9) 
Eye disorders 0 5 (4.3) 2 (3.4) 
Vision blurred 0 3 (2.6) 1 (1.7) 
Vascular disorders 4 (6.9) 1 (0.9) 4 (6.9) 
Hypertension 2 (3.4) 0 2 (3.4) 
Respiratory, thoracic and 
mediastinal disorders 4 (6.9) 11 (9.6) 4 (6.9) 
Cough 0 3 (2.6) 1 (1.7) 
Dyspnea 0 3 (2.6) 0 
Nasal congestion 2 (3.4) 0 0 
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Gastrointestinal disorders 8 (13.8) 20 (17.4) 10 (17.2) 
Nausea 2 (3.4) 6 (5.2) 3 (5.2) 
Diarrhea 3 (5.2) 5 (4.3) 1 (1.7) 
Abdominal pain 0  3 (2.6) 1 (1.7) 
Gastroesophageal reflux 
disease 0 5 (4.3) 1 (1.7) 
Toothache 2 (3.4) 2 (1.7) 0 
Skin and subcutaneous tissue 
disorders 6 (10.3) 9 (7.8) 8 (13.8) 
Rash 0 1 (0.9) 3 (5.2) 
Pruritus 2 (3.4) 1 (0.9) 1 (1.7) 
Musculoskeletal and connective 
tissue disorders 12 (20.7) 33 (28.7) 14 (24.1) 
Arthralgia 2 (3.4) 7 (6.1) 7 (12.1) 
Muscle spasms 0 8 (7.0) 3 (5.2) 
Myalgia 3 (5.2) 7 (6.1) 3 (5.2) 
Pain in extremity 1 (1.7) 4 (3.5) 3 (5.2) 
Back pain 0 6 (5.2) 2 (3.4) 
Muscular weakness 1 (1.7) 4 (3.5) 0 
Musculoskeletal pain 1 (1.7) 3 (2.6) 0 
Musculoskeletal stiffness 0 3 (2.6) 0 
Osteoarthritis 2 (3.4) 0 0 
Renal and urinary disorders 2 (3.4) 9 (7.8) 2 (3.4) 
Renal failure 1 (1.7) 4 (3.5) 0 
General disorders and 
administration site conditions 8 (13.8) 20 (17.4) 12 (20.7) 
Injection site reaction 0 4 (3.5) 8 (13.8) 
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Mild intensity* 0 3 (75.0) 8 (100) 
Moderate intensity* 0 1 (25.0) 0 
Severe intensity* 0 0 0 
Fatigue 0 5 (4.3) 4 (6.9) 
Feeling hot 2 (3.4) 0 0 
Non-cardiac chest pain 2 (3.4) 3 (2.6) 0 
Edema peripheral 4 (6.9) 3 (2.6) 0 
Injury, poisoning and procedural 
complications 6 (10.3) 12 (10.4) 5 (8.6) 
Fall 2 (3.4) 6 (5.2) 0 
Post-traumatic pain 0 3 (2.6) 1 (1.7) 
*In case of several occurrences, the maximal intensity is reported. 
75Q2W indicates 75 mg every 2 weeks (with possible dose adjustment to 150 mg every 2 weeks); 150Q4W, 150 
mg every 4 weeks (with possible dose adjustment to 150 mg every 2 weeks); TEAEs, treatment-emergent 
adverse events 
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Figure S1. Patient disposition for CHOICE II study 
 
75Q2W indicates 75 mg every 2 weeks (with possible dose adjustment to 150 mg every 2 weeks); 150Q4W, 150 
mg every 4 weeks (with possible dose adjustment to 150 mg every 2 weeks); ITT, intent-to-treat 
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Figure S2. Impact of dosing regimen adjustment on LDL-C levels (A) and free 
PCSK9 levels (B) in patients in the 75 mg Q2W alirocumab cohort: time profile 
from baseline to Week 24 (ITT analysis)  
(A) 
 
(B) 
 
Patients who received dose adjustment at Week 12 and had at least 1 subsequent injection. 
LDL-C indicates low-density lipoprotein cholesterol; LS, least-squares; Q2W, every 2 weeks; SE, standard error 
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Figure S3. The difference in percent change from baseline to Week 24 in LDL-C 
(alirocumab 150Q4W versus placebo) according to baseline subgroup: 
Demographics (A), medical history and PCSK9 levels (B), Lipids (C), and 
medication (D) (ITT analysis) 
(A) 
 
(B) 
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(C) 
 
(D) 
 
75Q2W indicates 75 mg every 2 weeks (with possible dose adjustment to 150 mg every 2 weeks); 150Q4W, 150 
mg every 4 weeks (with possible dose adjustment to 150 mg every 2 weeks); BMI, body mass index; CI, 
confidence interval; CKD, chronic kidney disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; Lp(a), lipoprotein(a); LS, least-squares; MI, myocardial infarction; PCSK9, 
proprotein convertase subtilisin/kexin type 9; SE, standard error; TGs, triglycerides. 
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Figure S4. Percent reduction in LDL-C at last value up to Week 24 by anti-
alirocumab antibody status in the alirocumab 150Q4W group (A) and 75Q2W 
group (B) (on-treatment analysis – modified ITT population). 
(A) 
 
(B) 
 
LDL-C indicates low-density lipoprotein-cholesterol. 
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